Comparative Pharmacology
Head-to-head clinical analysis: CELEXA versus KALEXATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELEXA versus KALEXATE.
CELEXA vs KALEXATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant